However, despite the promising clinical advances with CDK4/6 inhibitors, 15% of the ER+/HER2− breast cancer patients show de novo or early CDK4/6 inhibitors resistance and 50% develop clinical resistance with progression within 25 months [6]. This evidence concerns the gene ESR1 and breast cancer.